Biomarkers and Surrogate Endpoints in Renal Transplantation: Present Status and Considerations for Clinical Trial Design

American Journal of Transplantation

Volumn 4, Issue 4, 2004, Pages 451-457

  Lachenbruch, Peter A ^a   Rosenberg, Amy S ^a,d   Bonvini, Ezio ^a   Cavaillé Coll, Marc W ^b   Colvin, Robert B ^c  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^b Center for Drug Evaluation and Research   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d Office of Biotechnology Products   (United States)

Author keywords

Allograft rejection; Predictive variables; Surrogate endpoints

Indexed keywords

BIOLOGICAL MARKER; CREATININE; GRANZYME B;

ACCURACY; BIOSTATISTICS; CLINICAL RESEARCH; CLINICAL TRIAL; CORRELATION ANALYSIS; DISEASE MARKER; GRAFT SURVIVAL; HUMAN; KIDNEY ALLOGRAFT REJECTION; KIDNEY TRANSPLANTATION; OUTCOMES RESEARCH; PATIENT MONITORING; PRIORITY JOURNAL; PROGNOSIS; SHORT SURVEY; STATISTICAL MODEL; SURROGATE ENDPOINT;

BIOLOGICAL MARKERS; CLINICAL TRIALS; ENDPOINT DETERMINATION; GRAFT REJECTION; HUMANS; KIDNEY TRANSPLANTATION; REGRESSION ANALYSIS; RESEARCH DESIGN; RISK FACTORS;

EID: 1942534131     PISSN: 16006135     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2004.00386.x     Document Type: Short Survey

References (31)

1. Strehlau J, Pavlakis M, Lipman M et al. Quantitative detection of immune activation transcripts as a diagnostic tool in kidney transplantation. Proc Natl Acad Sci USA 1997; 94: 695.
2. Li B, Hartono C, Ding R et al. Noninvasive diagnosis of renal-allograft rejection by measurement of messenger RNA for perforin and granzyme B in urine. N Engl J Med 2001; 344: 947.
3. Kaplan B, Schold J, Meier-Kriesche HU. Poor predictive value of serum creatinine for renal allograft loss. Am J Transplant 2003.
4. Fisher L, Van Belle G. Biostatistics. A Methodology for the Health Sciences. New York: John Wiley and Sons, 1993.
5. Piantadosi S. Clinical Trials: a Methodologic Perspective. New York: John Wiley and Sons, 1997.
6. Pascual M, Vallhonrat H, Cosimi AB et al. The clinical usefulness of the renal allograft biopsy in the cyclosporine era: a prospective study. Transplantation 1999; 67: 737.
7. Racusen LC, Solez K, Colvin RB et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55: 713.
8. Colvin RB, Cohen AH, Saiontz C et al. Evaluation of pathologic criteria for acute renal allograft rejection: reproducibility, sensitivity, and clinical correlation. J Am Soc Nephrol 1997; 8: 1930.
9. Bates WD, Davies DR, Welsh K, Gray DW, Fuggle SV, Morris PJ. An evaluation of the Banff classification of early renal allograft biopsies and correlation with outcome. Nephrol Dial Transpl 1999; 14: 2364.
10. Nickeleit V, Vamvakas EC, Pascual M, Poletti BJ, Colvin RB. The prognostic significance of specific arterial lesions in acute renal allograft rejection. J Am Soc Nephrol 1998; 9: 1301.
11. Gaber LW, Moore LW, Gaber AO, Tesi RJ, Meyer J, Schroeder TJ. Correlation of histology to clinical rejection reversal: a thymoglobulin multicenter trial report. Kidney Int 1999; 55: 2415.
12. Mauiyyedi S, Crespo M, Collins AB et al. Acute humoral rejection in kidney transplantation. II. Morphology, immunopathology, and pathologic classification. J Am Soc Nephrol 2002; 13: 779.
13. Racusen LC, Colvin RB, Solez K et al. Antibody-mediated rejection criteria - an addition to the banff 97 classification of renal allograft rejection. Am J Transplant 2003; 3: 708.
14. Yilmaz S, Tomlanovich S, Mathew T et al. protocol core needle biopsy and histologic chronic allograft damage index (CADI) as surrogate end point for long-term graft survival in multicenter studies. J Am Soc Nephrol 2003; 14: 773.
15. Mauiyyedi S, Pelle PD, Saidman S et al. Chronic humoral rejection: identification of antibody-mediated chronic renal allograft rejection by C4d deposits in peritubular capillaries. J Am Soc Nephrol 2001; 12: 574.
16. Regele H, Bohmig GA, Habicht A et al. Capillary deposition of complement split product C4d in renal allografts is associated with basement membrane injury in peritubular and glomerular capillaries: a contribution of humoral immunity to chronic allograft rejection. J Am Soc Nephrol 2002; 13: 2371.
17. Kirk AD, Jacobson LM, Heisey DM, Radke NF, Pirsch JD, Sollinger HW. Clinically stable human renal allografts contain histological and RNA- based findings that correlate with deteriorating graft function. Transplantation 1999; 68: 1578.
18. Nankivell BJ, Fenton-Lee CA, Kuypers DR et al. Effect of histological damage on long-term kidney transplant outcome. Transplantation 2001; 71: 515.
19. Seron D, Moreso F, Ramon JM et al. Protocol renal allograft biopsies and the design of clinical trials aimed to prevent or treat chronic allograft nephropathy. Transplantation 2000; 69: 1849.
20. Nicholson ML, Bailey E, Williams S, Harris KP, Furness PN. Computerized histomorphometric assessment of protocol renal transplant biopsy specimens for surrogate markers of chronic rejection. Transplantation 1999; 68: 236.
21. Furness PN, Taub N, Assmann KJ et al. International variation in histologic grading is large, and persistent feedback does not improve reproducibility. Am J Surg Pathol 2003; 27: 805.
22. Grimm PC, Nickerson P, Gough J et al. Computerized image analysis of Sirius Red-stained renal allograft biopsies as a surrogate marker to predict long-term allograft function. J Am Soc Nephrol 2003; 14: 1662.
23. Filler G, Browne R, Seikaly MG. Glomerular filtration rate as a putative 'surrogate end-point' for renal transplant clinical trials in children. Pediatr Transplant 2003; 7: 18.
24. Eikmans M, Sijpkens YW, Baelde HJ, de Heer E, Paul LC, Bruijn JA. High transforming growth factor-beta and extracellular matrix mRNA response in renal allografts during early acute rejection is associated with absence of chronic rejection. Transplantation 2002; 73: 573.
25. Scherer A, Krause A, Walker JR, Korn A, Niese D, Raulf F. Early prognosis of the development of renal chronic allograft rejection by gene expression profiling of human protocol biopsies. Transplantation 2003; 75: 1323.
26. Sabek O, Dorak MT, Kotb M, Gaber AO, Gaber L. Quantitative detection of T-cell activation markers by real-time PCR in renal transplant rejection and correlation with histopathologic evaluation. Transplantation 2002; 74: 701.
27. Dugre FJ, Gaudreau S, Belles-Isles M, Houde I, Roy R. Cytokine and cytotoxic molecule gene expression determined in peripheral blood mononuclear cells in the diagnosis of acute renal rejection. Transplantation 2000; 70: 1074.
28. Satterwhite T, Chua MS, Hsieh SC et al. Increased expression of cytotoxic effector molecules: Different interpretations for steroid-based and steroid-free immunosuppression. Pediatr Transplant 2003; 7: 53.
29. Karpinski M, Rush D, Jeffery J, Pochinco D, Milley D, Nickerson P. Heightened peripheral blood lymphocyte CD69 expression is neither sensitive nor specific as a noninvasive diagnostic test for renal allograft rejection. J Am Soc Nephrol 2003; 14: 226.
30. Akalin E, Hendrix RC, Polavarapu RG et al. Gene expression analysis in human renal allograft biopsy samples using high-density oligoarray technology. Transplantation 2001; 72: 948.
31. Sarwal M, Chua MS, Kambham N et al. Molecular heterogeneity in acute renal allograft rejection identified by DNA microarray profiling. N Engl J Med 2003; 349: 125.